Search clinical trials for: Canagliflozin

Total 656 results

Beijing Anzhen Hospital

Recruiting

The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

Coronary Artery Disease | Diabete Mellitus

China
University of Turin, Italy

Unknown

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors (GliRACo1)

Diabetes Mellitus, Type 2 | Body Weight Changes | Arterial Hypertension

Italy
Brigham and Women's Hospital

Unknown

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

Diabetes Mellitus, Type 2

United States
Janssen-Cilag International NV

Completed

A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers

Healthy

Germany
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

Janagliflozin Treat T2DM Monotherapy

Diabetes Type 2

China
Center for Outcomes Research and Clinical Epidemiology...
Italian Society of Diabetology

Not yet recruiting

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial (GOLDEN-AGE)

Diabetes Mellitus, Type 2
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Peking Union Medical College Hospital

Unknown

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers

Healthy
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Brazil
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Healthy

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

Type 1 Diabetes

United States
Janssen Research & Development, LLC

Completed

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (CANVAS-R)

Diabetes Mellitus, Type 2 | Albuminuria

Australia, France, Italy, Poland, Ukraine, United Kingdom, United States, China, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Malaysia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Puerto... and more
Janssen Research & Development, LLC

Completed

A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

Diabetes Mellitus, Type 1

United States, Canada
Janssen Research & Development, LLC

Completed

A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

Diabetes Mellitus, Type 2

China, Malaysia, Vietnam
The Cleveland Clinic
Janssen Scientific Affairs, LLC

Terminated

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

Obesity | Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS)

Cardiovascular Diseases | Diabetes Mellitus, Type 2 | Risk Factors

United States, Australia, Poland, Ukraine, United Kingdom, Belgium, Germany, France, Spain, Argentina, Colombia, Israel, Mexico, India, Canada, Netherlands, Sweden, Malaysia, New Zealand, Estonia, Russian Federation, Hungary, Norway, ... and more
The University of Texas Health Science Center at...
Janssen Scientific Affairs, LLC

Withdrawn

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Cardiovascular Diseases | Type2 Diabetes Mellitus

United States
Eli Lilly and Company

Completed

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (AWARD-10)

Type 2 Diabetes Mellitus

Czechia, Hungary, United States, Mexico, Germany, Austria, Israel, Puerto Rico, Spain
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Diabetes Mellitus, Type 2

United States, Ukraine, Argentina, Mexico, Romania, South Africa, Korea, Republic of, Russian Federation, Brazil, Puerto Rico, Hungary, Slovakia, Czechia
Qian geng

Recruiting

Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction (Health)

Myocardial Infarction | Heart Failure

China
Janssen Research & Development, LLC

Completed

An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Diabetes Mellitus, Type 2

United States, Romania, Canada, Russian Federation, Czech Republic, Slovakia, Mexico
Janssen Research & Development, LLC

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers

Healthy

China
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Diabetes Mellitus, Type 2

United States, Australia, Germany, Canada, France
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Healthy

India
Janssen Research & Development, LLC

Completed

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

France, Poland, United Kingdom, United States, Spain, Colombia, India, Romania, South Africa, Ukraine, Australia, Canada, Greece, Sweden, New Zealand, Switzerland, Hong Kong
Janssen Research & Development, LLC

Completed

A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

Healthy

United States
Dong-A ST Co., Ltd.

Completed

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Type2 Diabetes

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Completed

The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers

Type 2 Diabetes

China
AstraZeneca

Recruiting

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) (ZEAL)

Liver Cirrhosis

Spain, Denmark, Germany, United States, China, Australia, Belgium, Netherlands, Switzerland, Austria, Taiwan, Canada, Czechia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers

Healthy
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

Healthy | Renal Insufficiency

United States
AstraZeneca
Bristol-Myers Squibb

Completed

To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately

Type 2 Diabetes Mellitus

United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Drug-drug Interaction of SHR3824 and SP2086

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers (SHR3824)

Type 2 Diabetes

China
Janssen Research & Development, LLC

Completed

A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, India, China, Brazil, Greece, Malaysia, Mexico, Philippines, Poland, Russian Federation
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers

Healthy
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
AstraZeneca

Not yet recruiting

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease. (MIRO-CKD)

Chronic Kidney Disease

United States, Austria, Italy, Spain, Canada, Malaysia, Taiwan, Poland, Bulgaria
Johnson & Johnson Private Limited

Completed

A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting

Diabetes Mellitus, Type 2

India
Hospital Universitari Vall d'Hebron Research Institute

Unknown

Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB) (CANA-PHH-RYGB)

Postprandial Hypoglycemia

Spain

3

Subscribe